News & Updates

The monoclonal antibody sarilumab demonstrated significant efficacy in individuals with relapsing polymyalgia rheumatica (PMR), findings from the phase III SAPHYR trial have shown.

Crohn’s disease (CD) remission, induced by either CD exclusion diet with partial enteral nutrition (CDED+PEN) or by exclusive enteral nutrition (EEN), leads to significant changes in metabolite levels in paediatric patients, according to a new study.

The fixed-dose combination of trifluridine/tipiracil may be feasible for use in the treatment of patients with refractory esophageal squamous cell carcinoma (ESCC), with the drug showing modest clinical activity in the phase II ECTAS study.

Elevated levels of sialylated human milk oligosaccharides (HMO) in mothers’ breastmilk appears to worsen infant nutritional status, reports a Bangladesh study.

Out-of-hospital cardiac arrest (OHCA) tend to occur at a higher rate among patients with rheumatoid arthritis (RA), and this risk increase is especially pronounced in women but not observed in men, a study has found.

New drug applications approved by US FDA as of 01 - 15 June 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Drug combinations including venetoclax seem to have a positive impact on health-related quality of life (HRQoL), or at least does not worsen it, in patients with acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy, a recent study has found.

Older outpatients with delayed/prolonged orthostatic hypotension (DPOH) are at higher risk of mortality, reveals a study. The magnitude of both systolic and diastolic OH is also associated with increased death.